AU Patent

AU2020336017A1 — Methods for the administration of certain VMAT2 inhibitors to patients with severe renal impairment

Assigned to Neurocrine Biosciences Inc · Expires 2022-04-07 · 4y expired

What this patent protects

Provided is a method of administering a vesicular monoamine transporter 2 (VMAT2) inhibitor to a subject in need thereof, wherein the subject has severe renal impairment.

USPTO Abstract

Provided is a method of administering a vesicular monoamine transporter 2 (VMAT2) inhibitor to a subject in need thereof, wherein the subject has severe renal impairment.

Drugs covered by this patent

Patent Metadata

Patent number
AU2020336017A1
Jurisdiction
AU
Classification
—
Expires
2022-04-07
Drug substance claim
No
Drug product claim
No
Assignee
Neurocrine Biosciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.